If you think a drug you're taking might be causing your depression, you may be right. Certain medications prescribed for various medical conditions do cause such feelings as sadness, despair, and ...

President Donald Trump’s second term and the Supreme Court’s conservative activism have lit a fire in Republicans, who are targeting same-sex marriage as part of a broader attack on LGBTQ+ rights.

1 Department of Magnetic Resonance Imaging, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 2 Zhengzhou Key Laboratory of Brain Function and Cognitive Magnetic Resonance ...

Karnataka: Shilpa Medicare Limited has received approval from the US Food and Drugs Administration (USFDA) for Varenicline Tablets, 0.5 and 1 mg. The total US market for this product is around 203 M ...

while Shilpa Medicare shares fall 5 percent despite USFDA approval for Varenicline tablets. Also Read: TCS Q4 preview: modest growth expected amid seasonal weakness Wipro, SBI, Tech Mahindra ...

Shilpa Medicare has received approval from USFDA for Varenicline Tablets, 0.5 and 1 mg. The total US market for this product is around 203 M USD. Shilpa's product has been approved as a generic ...

Shilpa Medicare said that it has received approval from United States Food and Drug Administration (USFDA) for Varenicline tablets, 0.5 and 1 mg. Varenicline helps people quit smoking by blocking the ...

LaShell Robinson, head of global feasibility and trial equity at Takeda, talks about Takeda's aims to expand its efforts globally by adapting strategies to regional needs. In this Pharmaceutical ...

The nicotinic acetylcholine receptors (nAChRs) are the most well understood membrane receptors for neurotransmitters at the structural and functional level. They are integral allosteric membrane ...

Champix fans in Medway are celebrating this April following the launch of the stop smoking drug Varenicline, available from the Medway Stop Smoking Service. A branded version of the stop smoking ...

Get Instant Summarized Text (Gist) Mavoglurant, initially developed for fragile X syndrome, shows promise in reducing cocaine use disorder. A Phase II clinical trial with 68 participants revealed ...